Do you offer GMP manufacturing for clinical trials?

No. Our services are strictly focused on preclinical research and development (Research Grade and GLP-like studies). We do not produce vaccines for human clinical administration.

Next-Gen Dendritic Cell Vaccine Development

Q: What sources of Dendritic Cells do you use for vaccine development?

For murine models, we primarily generate Bone Marrow-Derived DCs (BMDCs) from C57BL/6 or BALB/c mice. For human-focused studies, we differentiate Monocyte-Derived DCs (MoDCs) from PBMCs or use CD34+ progenitor cells.

Dendritic cells (DCs) act as the "conductors" of the immune system, bridging innate and adaptive immunity by processing antigens and presenting them to T cells. While DC vaccines hold immense promise, their efficacy depends heavily on optimal maturation, antigen loading strategy, and migration efficiency.

Creative Biolabs offers a comprehensive dendritic cell vaccine development service dedicated to preclinical research. Unlike standard protocols, we specialize in high-performance DC engineering—from generating bone marrow-derived DCs (BMDCs) to advanced antigen pulsing with mRNA or viral vectors. We empower researchers to develop potent cellular immunotherapies with validated in vivo antitumor activity.

Get a Quote

Overcoming Bottlenecks in DC Vaccinology

Developing an effective DC vaccine requires navigating complex biological challenges that often limit preclinical success:

▶ Suboptimal Maturation: Immature DCs can induce immune tolerance rather than activation. Standard protocols often fail to produce fully mature, IL-12 secreting DCs required for Th1 polarization.
▶ Inefficient Antigen Loading: Passive peptide pulsing is often transient. Achieving durable antigen presentation via mRNA electroporation or viral transduction is technically demanding.
▶ Tumor Microenvironment (TME) Suppression: Even successfully primed T cells may be inactivated by the immunosuppressive TME, necessitating the development of engineered DCs that can resist suppression.
▶ Migration Deficits: Only a fraction of injected DCs typically reach the draining lymph nodes. Optimization of administration routes and migration factors is critical.

Consult Our Experts

Our Innovative Solutions

Creative Biolabs combines decades of immunology expertise with cutting-edge cellular engineering to maximize DC vaccine potency:

High-Purity DC Generation

Robust protocols for generating Bone Marrow-Derived DCs (BMDCs) or Monocyte-Derived DCs (MoDCs) with >90% purity and high viability.

Multi-Modal Antigen Loading

Beyond simple pulsing: we offer electroporation of mRNA, lentiviral transduction, and loading with tumor lysates or exosomes.

Maturation Cocktail Optimization

Custom screening of cytokine cocktails (e.g., GM-CSF, IL-4, TNF-α, LPS, Poly I:C) to ensure optimal expression of co-stimulatory molecules (CD80/86).

Functional Potency Assays

Rigorous validation using Mixed Lymphocyte Reaction (MLR) and antigen-specific T-cell killing assays to confirm vaccine bioactivity.

Featured Preclinical Services

We provide a complete toolkit for developing and testing dendritic cell-based immunotherapies:

Custom DC Generation (Mouse/Human)

We isolate precursors from mouse bone marrow (BALB/c, C57BL/6) or human PBMCs. Using optimized GM-CSF/IL-4 protocols, we differentiate them into immature DCs and trigger maturation using TLR agonists to generate potent APCs ready for antigen loading.

Learn More →

Advanced Antigen Loading Services

We offer diverse strategies to introduce antigens into DCs: peptide pulsing for MHC-I/II presentation, tumor lysate co-incubation for broad antigen coverage, and mRNA electroporation for sustained antigen expression and enhanced cross-presentation.

Learn More →

In Vivo Efficacy Evaluation

We test prophylactic and therapeutic efficacy in syngeneic tumor models (e.g., Melanoma B16, Colon CT26). Services include tumor volume monitoring, survival analysis, and ELISpot assessment of splenocytes to verify systemic immune memory.

Learn More →

DC Phenotyping & Quality Control

Before release, every DC batch undergoes rigorous QC. We use multi-color flow cytometry to verify maturation markers (CD11c, CD80, CD86, MHC-II) and ELISA to measure key cytokines (IL-12p70, IFN-γ) indicative of Th1-polarizing potential.

Learn More →

Preclinical Development Workflow

From bone marrow to bioactive vaccine, our optimized pipeline ensures high-quality data:

Step 1: Precursor Isolation

Activity: Harvesting bone marrow from femurs/tibias of mice (e.g., C57BL/6) or isolating monocytes from human PBMCs.

Outcome: High-yield precursor population.

Step 2: Differentiation & Culture

Activity: Culturing cells with GM-CSF and IL-4 for 5-7 days to induce differentiation into immature DCs (iDCs).

Outcome: Generation of CD11c+ iDCs.

Step 3: Antigen Loading (Pulsing)

Activity: Incubating iDCs with specific peptides, proteins, tumor lysates, or transfecting with mRNA to internalize the antigen.

Outcome: Antigen-loaded DCs capable of processing targets.

Step 4: Maturation Induction

Activity: Adding maturation cocktails (e.g., LPS, TNF-α, CD40L) to trigger upregulation of co-stimulatory molecules.

Outcome: Mature DCs (mDCs) ready for presentation.

Step 5: In Vitro Quality Control

Activity: Flow cytometry for phenotype (MHC-II high, CD86 high) and Mixed Lymphocyte Reaction (MLR) for T-cell proliferation.

Outcome: Validated vaccine batch with confirmed potency.

Step 6: In Vivo Vaccination

Activity: Injecting mDCs into tumor-bearing mice (Therapeutic) or naive mice (Prophylactic) via footpad or IV injection.

Outcome: Efficacy data: Tumor growth inhibition and survival curves.

Customize Your Workflow

Technology Platforms

Our DC vaccine services are supported by advanced technological platforms tailored for cellular immunotherapy:

Enabling non-viral, high-efficiency loading of RNA and DNA.

Optimized pulse protocols for high viability
Superior antigen expression compared to passive pulsing
Capable of loading multiple mRNA antigens simultaneously

Comprehensive characterization of DC phenotype and function.

Multi-color panels (up to 18 parameters) for surface markers
Intracellular cytokine staining (ICS) for IL-12
Assessment of antigen uptake via fluorescent tracers

Evaluating the functional outcome of DC vaccination.

Antigen-specific T-cell proliferation assays (CFSE dilution)
Cytotoxic T Lymphocyte (CTL) killing assays
ELISpot for IFN-γ secretion quantification

Specialized models for testing human DC vaccines.

NSG/NOG mice reconstituted with human immune systems
Allows testing of human-derived DCs in an in vivo setting
Evaluation of human T-cell priming and tumor control

High-Efficiency Electroporation

High-Dimensional Flow Cytometry

T-Cell Functional Assays

Humanized Mouse Models

Explore Our Technologies

Why Partner with Creative Biolabs?

Cellular Expertise

Proven track record in generating difficult-to-culture primary cells with high purity and functionality.

Flexible Models

Wide range of syngeneic tumor models (Melanoma, Breast, Lung, Colon) to match your target indication.

One-Stop Service

Seamless integration of antigen synthesis, DC generation, and in vivo testing under one roof.

Data Quality

Comprehensive reporting with raw data, ensuring reproducibility and readiness for IND filing support.

Request a Proposal

Mechanism & Application

Dendritic Cell vaccines work by leveraging the body's natural antigen-presenting machinery. The process involves loading autologous DCs with tumor antigens ex vivo and re-infusing them to prime potent CD4+ and CD8+ T-cell responses.

Critical Success Factors:

✓ Antigen Presentation: Efficient processing and presentation of peptides on MHC-I (cross-presentation) and MHC-II molecules.
✓ Maturation Status: Only mature DCs expressing high levels of CD80, CD86, and CD40 can effectively prime naive T cells without inducing anergy.
✓ Th1 Polarization: Secretion of IL-12 by DCs is essential for driving a strong cytotoxic (CTL) immune response against the tumor.

Learn About Mechanism Studies

Frequently Asked Questions

Q: What sources of Dendritic Cells do you use for vaccine development?

A: For murine models, we primarily generate bone marrow-derived DCs (BMDCs) from C57BL/6 or BALB/c mice. For human-focused studies, we differentiate Monocyte-Derived DCs (MoDCs) from PBMCs or use CD34+ progenitor cells.

Q: What is the most effective method for antigen loading?

A: It depends on the antigen type. Peptide pulsing is simple but HLA-restricted. mRNA electroporation and viral transduction enable prolonged antigen expression and are HLA-independent, often leading to better cross-presentation.

Q: How do you verify that the DCs are mature and functional?

A: We use flow cytometry to assess the upregulation of surface markers CD80, CD86, CD40, and MHC-II. Functionally, we measure IL-12 secretion via ELISA and assess T-cell priming capacity using Mixed Lymphocyte Reaction (MLR) assays.

Q: Can you perform efficacy studies using human DCs?

A: Yes. We utilize immunodeficient mice (e.g., NSG) reconstituted with a human immune system (humanized mice). This allows us to evaluate the interaction between human DCs and human T cells in an in vivo setting.

Q: What does your dendritic cell vaccine development solution include?

A: We offer a fully integrated platform for pre-clinical DC vaccine research. Our services encompass dendritic cell generation and differentiation from various sources, antigen loading optimization, maturation induction, in vitro quality control (phenotypic and functional characterization), and in vivo efficacy evaluation in animal models.

Speak With a Scientist

Related Resources